HIPAA Protections for Online Lab Tests: What You Need to Know
- As companies combine genetic and non-genetic information into proprietary, integrated risk reports and predictions (Function Health, as an example, sells risk reports for heart and brain health, combining...
- Okay, here's a breakdown of the key takeaways from the provided text, focusing on the privacy and legal concerns surrounding direct-to-consumer (DTC) health and genetic testing companies like...
- * Not Fully Covered by HIPAA: These companies often argue they aren't "covered entities" under HIPAA (Health Insurance Portability and Accountability act) because they don't always function as...
As more Americans sidestep doctors’ offices to order lab tests adn genetic screenings online,privacy experts warn that the new trove of sensitive health data could end up in the hands of companies selling certain types of insurance,lenders,employers,or law enforcement.
Patients’ health data are typically protected under the Health Insurance Portability and Accountability Act,or HIPAA. But that federal law only applies to hospitals, physician practices, and other entities involved in coordinating or paying for patient care. The new breed of startups that sell blood panels and genetic tests - typically not covered by health insurance – directly to consumers aren’t always considered medical providers as defined by the law.”these tests kind of feel like medical tests, but they may not always be covered by HIPAA,” said Anna Wexler, an assistant professor of medical ethics at the University of Pennsylvania who has studied direct-to-consumer health companies‘ privacy practices. “Many of these companies do exist outside of the customary medical environment.”
As more people rush to direct-to-consumer health tests driven by a desire to catch cancer before symptoms emerge or to find out if they are at risk for Alzheimer’s, experts say it’s conceivable that banks and insurers could use any health data they can to mitigate their own risks. That could impact financial products such as loans, life insurance, short-term health insurance used by gig workers and those between jobs, and long-term health insurance that pays for nursing home stays.
“If you don’t agree [to share the data], you don’t get the policy, you don’t get the bank loan, whatever you’re applying toward,” said Mark Rothstein, director of translational bioethics at UC Irvine.
Function Health, for example, which offers over 100 tests for an annual subscription fee of $365, says on its website that it is “not a laboratory or medical provider.” The startup, co-founded by health secretary Robert F. Kennedy Jr. ally Mark Hyman, says it “does not offer medical advice, laboratory services, a diagnosis, medical treatment, or any form of medical opinion, through our services or otherwise,”
If someone’s taken a full-body scan or a genetic risk assessment, for instance, it’s not far-fetched or clearly illegal for an employer conditionally offering a job requiring certain physical traits to “get access to [the test results] and see that their [potential] employee, who they want to hire, is not healthy or has some abnormal scan information,” Wexler said. “those could be used to make employment decisions.”
Function, and other direct-to-consumer health test companies such as Prenuvo and hims also say in their privacy policies that they’ll share sensitive health records in response to valid requests from law enforcement like a court-ordered subpoena. (At the
As companies combine genetic and non-genetic information into proprietary, integrated risk reports and predictions (Function Health, as an example, sells risk reports for heart and brain health, combining blood biomarkers with genetic assessments) “consumer protections become murkier,” because they’re not explicitly outlined in existing data protection laws, meaning enterprising life, disability, or short-term insurers and some employers could potentially make a case for demanding them from the customers, or the companies selling them, Sklar said. While Function said it does not directly share data with third-party insurers, it did not respond to STAT’s request for clarification on privacy protections for risk scores.
<
Okay, here’s a breakdown of the key takeaways from the provided text, focusing on the privacy and legal concerns surrounding direct-to-consumer (DTC) health and genetic testing companies like Function, Prenuvo, and Hims:
1. Privacy Concerns & HIPAA Limitations:
* Not Fully Covered by HIPAA: These companies often argue they aren’t “covered entities” under HIPAA (Health Insurance Portability and Accountability act) because they don’t always function as traditional medical providers, and sometimes operate on a cash-pay basis. This means they aren’t legally required to adhere to HIPAA’s strict data sharing restrictions.
* Data Sharing is Possible: Despite emphasizing privacy, their policies do allow for data sharing in certain situations:
* With corporate affiliates.
* In response to lawful requests from law enforcement or government agencies.
* Recent Court Rulings: Federal court rulings are weakening reproductive health data protections, and a Texas court blocked biden-era HIPAA modifications aimed at strengthening those protections. This creates a broader vulnerability for health data privacy.
2. Legal and Regulatory Landscape is Evolving & Uncertain:
* Attacks on Health Privacy: The court rulings are seen as “attacks on health care and health privacy.”
* Unclear Protections: The extent of legal protections for genetic information is still being “tested.” It’s unclear how far those protections go in different circumstances.
3. Potential Insurance Impacts:
* Insurance Eligibility: Genetic test results can be used by some insurance companies (especially specialty plans) to determine eligibility or premiums.
* Life Insurance: Results could potentially affect the ability to obtain life insurance.
* Weighing Risks & Benefits: Genetic counselors are advising patients to carefully consider the potential insurance implications before undergoing DTC genetic testing.
4. Accuracy & Validation of Tests:
* Questionable Validity: There are open questions about the accuracy and clinical validation of some DTC tests, particularly those predicting risks for complex conditions like Alzheimer’s or cancer.The calculations used are often proprietary and not fully vetted.
In essence, the article highlights a growing concern that while DTC health and genetic testing offers convenience, it comes with meaningful privacy risks and potential unintended consequences related to insurance and data security, especially as the legal framework surrounding these technologies is still developing.
